… Introduction: In-stent restenosis (ISR) has been one of the biggest limitations to the success
… The introduction of drug-eluting stent (DES) was a revolution in the treatment of CAD …

… Drug-eluting stents (DES) were developed to overcome in-stent restenosis (ISR), which has
… ISR cannot be still ignored in the current DES era [6]. Although the low frequency of DES …

… the in-stent restenosis (ISR) progression rates of different 2nd-generation drug-eluting stents
(… TLR occurred in 58 lesions (6.1%) during the first angiographic follow-up period and 23 de …

… in-stent restenosis. Much of the present understanding of this condition stems from studies on
in-stent restenosis, … of which in the DES-era is debatable. The recently described Waksman …

… an alternative to bare metal stents (BMS) arose from the high rates of in-stent restenosis (ISR)
and … drug following this brief period led to unexpectedly high rates of restenosis and repeat …

… in-stent restenosis (ISR) following percutaneous coronary intervention (PCI). This study aimed
to examine the presentation and outcomes of drug-eluting stent (… the drugeluting stent era. …

… Is this true for restenosis after drug-eluting stent (DES) implantation and factors associated
with it? The main objective of the study was to determine the rate of in-stent restenosis (ISR) …

… In second- and third-generation drug-eluting stent (DES) era, in-stent restenosis (ISR) is
not commonly seen but is still encountered occasionally. Improvement of stent platform and …

… Approximately, 10–20% of patients with drug eluting stent (DES) in-stent restenosis (ISR)
will … We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting …

… In-stent restenosis continues to be an important problem even in the current DES era
because of the propensity to present as ACS. Close monitoring of patients with ACS ISR …